Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production.
We have previously shown that retinoids can induce differentiation of B cells in vitro as well as in vivo in patients with common variable immunodeficiency (CVI). While changes were observed over 1 week when retinoic acid (RA) was added to CVI hybridoma cells in vitro, maturation of the patients' B-cell compartment in vivo occurred only after 4 months of drug administration. We have now performed a 64-week open trial of oral 13-cis RA in five patients to see if prolonged treatment would result in continued improvement in their humoral immune compartment. In this trial, drug was given for 32 weeks followed by a 32-week wash-out period. During the treatment, the patients showed changes in a variety of parameters indicating an alteration towards normal of their humoral immune systems. This change included a fall in the elevated circulating interleukin-6 (IL-6) levels, a more normal display of B-cell surface markers (L-selectin and CD20), a decrease in B-cell size, and improved in vitro and in vivo B-cell function. In order to determine if VH gene use was affected by the retinoid treatment, VH gene expression in the CVI patients was characterized. Results showed an unusual predominance of non-mutated VH gene sequences, representative of cells that are recent bone marrow emigrants. While no common pattern of change occurred in VH gene segment use in the patients while on retinoid therapy, large-scale (> 10-fold) changes in the expression of these genes were observed in each individual over time. Taken together, these results provide multiple lines of evidence that 13-cis RA promotes maturation of B cells in patients with CVI. However, the effect appears to be partial, such that stimuli in addition to 13-cis RA will be necessary to provide for further B-cell differentiation in order to achieve normalization of humoral immunity.
Saxon
A
A
Hart and Louise Lyon Laboratory, Department of Medicine, University of California, Los Angeles School of Medicine 90024-1680.
Keld
B
B
Braun
J
J
Dotson
A
A
Sidell
N
N
D000293:Adolescent; D000328:Adult; D000954:Antigens, Surface / Q000032:analysis; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D001483:Base Sequence; D002454:Cell Differentiation / Q000187:drug effects; D017074:Common Variable Immunodeficiency / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D005260:Female; D015870:Gene Expression / Q000276:immunology; D005803:Genes, Immunoglobulin / Q000276:immunology; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007136:Immunoglobulins / Q000097:blood; D015850:Interleukin-6 / Q000097:blood*; D015474:Isotretinoin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009841:Oligonucleotides / Q000737:chemistry
D000954:Antigens, Surface; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D015850:Interleukin-6; D009841:Oligonucleotides; D015474:Isotretinoin